2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2239

Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2280

Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2678

Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2617

Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2089

Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

9:00AM-11:00AM: Abstract Number: 2232

Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2544

Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2125

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2158

Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2138

Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2139

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2228

Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2114

Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2170

Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2108

Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients

Infection-Related Rheumatic Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].